



LAW OFFICES OF  
**SYNNESTVEDT & LECHNER LLP**  
2600 ARAMARK TOWER  
1101 MARKET STREET  
PHILADELPHIA, PA 19107-2950  
TELEPHONE (215) 923-4466  
FACSIMILE (215) 923-2189  
E-MAIL [synnlech@synnlech.com](mailto:synnlech@synnlech.com)  
[www.synnlech.com](http://www.synnlech.com)

SP. 1615  
JAN 29 2001  
TECH CENTER 1600/2900

RECEIVED  
JAN 29 2001

January 22, 2001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of Kenneth I. Cummings and Zebrunnissa Ramtoola  
Application No. 09/510,560

Art Unit 1615

Filed February 22, 2000

Solid Oral Dosage Form Containing an Enhancer

(Attorney Docket No. P 24,375-A USA)

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on Monday, January 22, 2001.

  
Marge L. Iaconelli

Commissioner for Patents  
Washington, DC 20231

**SUBMISSION OF INFORMATION**  
**DISCLOSURE STATEMENT PURSUANT TO 37 CFR §1.97(b)**

Sir:

Pursuant to 37 CFR §1.97(b), enclosed herewith is "Form PTO-1449 Modified". The status of the present application is that applicants are awaiting a first Action on the merits.

Application No. 09/510,560  
Art Unit 1615  
Page 2

January 22, 2001

**Summary of the Invention**

The present invention relates to a solid oral dosage form comprising: (A) a pharmaceutically-active ingredient; and (B) an enhancer which enhances the bioavailability and/or the absorption of said pharmaceutically-active ingredient.

The invention of the present application is defined in the following claim forms: (A) a solid oral dosage form comprising a pharmaceutically active ingredient and an enhancer which enhances the bioavailability and/or the absorption of said pharmaceutically-active ingredient; (B) a method of treatment of a medical condition comprising the step of administering to a patient the solid oral dosage form described in (A); and (C) a process for the manufacture of the solid oral dosage form described in (A).

**The Publications**

Copies of the following publications are enclosed.

Documents AA to AD, AG, AI, AJ, AM, and AN on Sheet 1 and Documents AA to AD and AG to AI on Sheet 2 relate to the use of an enhancer which enhances the bioavailability and/or the absorption of a pharmaceutically-active ingredient.

Documents AH and AK on Sheet 1 relate to a solid oral dosage form comprising: (A) a pharmaceutically active agent; and (B) a film-coating which dissolves at certain pH values.

Document AL on Sheet 1 relates to a method for making pharmaceutical tablets.

Documents AE and AF on Sheet 2 relate to a model for studying drug absorption.

Application No. 09/510,560  
Art Unit 1615  
Page 3

January 22, 2001

Document AC on Sheet 1 is an English-language equivalent of EP 0,370,481. Documents AL to AN on Sheet 1 are English-language abstracts of foreign patents.

The Commissioner is hereby authorized to charge any fee associated with this communication to Deposit Account No. 19-5425. A duplicate of this letter is attached.

Respectfully submitted,



Gene J. Yao, Esquire  
Registration No. 47,193

SYNNESTVEDT & LECHNER LLP  
Suite 2600 Aramark Tower  
1101 Market Street  
Philadelphia, PA 19107  
(215) 923-4466

M:\GYao\24,375-A USA\PTO Correspondence\IDS Transmittal Cover.2.wpd